Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 314

1.

Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT.

Battipaglia G, Boumendil A, Labopin M, Ciceri F, Tischer J, Stelljes M, Ehninger G, Beelen D, Finke J, Van Lint MT, Eder M, Afanasyev B, Fanin R, Mohty M, Ruggeri A, Nagler A.

Bone Marrow Transplant. 2019 Feb 4. doi: 10.1038/s41409-019-0459-7. [Epub ahead of print]

PMID:
30718798
2.

Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).

Guillaume-Jugnot P, Badoglio M, Labopin M, Terriou L, Yakoub-Agha I, Martin T, Lioure B, Marjanovic Z, Blaise D, Nguyen S, Pugnet G, Huynh A, Deligny C, Seinturier C, Garban F, Swiader L, Bay JO, Braun T, de Latour RP, Rubio MT, Farge D.

Clin Rheumatol. 2019 Jan 21. doi: 10.1007/s10067-019-04435-2. [Epub ahead of print]

PMID:
30663016
3.

Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia over 45 years of age.

Santoro N, Labopin M, Ciceri F, Van Lint MT, Nasso D, Blaise D, Arcese W, Tischer J, Bruno B, Ehninger G, Koc Y, Santarone S, Huang XJ, Savani BN, Mohty M, Ruggeri A, Nagler A.

Cancer. 2019 Jan 8. doi: 10.1002/cncr.31941. [Epub ahead of print]

PMID:
30620383
4.

Comparative outcomes of myeloablative and reduced-intensity conditioning allogeneic hematopoietic cell transplantation for therapy-related acute myeloid leukemia with prior solid tumor: A report from the acute leukemia working party of the European society for blood and bone marrow transplantation.

Lee CJ, Labopin M, Beelen D, Finke J, Blaise D, Ganser A, Itälä-Remes M, Chevallier P, Labussière-Wallet H, Maertens J, Yakoub-Agha I, Bourhis JH, Mailhol A, Mohty M, Savani BN, Nagler A.

Am J Hematol. 2018 Dec 30. doi: 10.1002/ajh.25395. [Epub ahead of print]

PMID:
30597620
5.

Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC.

Bourgeois AL, Labopin M, Leclerc M, de Latour RP, Bourhis JH, Ceballos P, Orvain C, Wallet HL, Bilger K, Blaise D, Rubio MT, Guillaume T, Mohty M, Chevallier P; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Oncotarget. 2018 Nov 27;9(93):36603-36612. doi: 10.18632/oncotarget.26391. eCollection 2018 Nov 27.

6.

Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission.

Baron F, Labopin M, Ruggeri A, Volt F, Mohty M, Blaise D, Chevallier P, Sanz J, Fegueux N, Cornelissen JJ, Rambaldi A, Savani BN, Gluckman E, Nagler A.

J Intern Med. 2018 Dec 18. doi: 10.1111/joim.12870. [Epub ahead of print]

PMID:
30561052
7.

Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT.

Giebel S, Labopin M, Czerw T, Socié G, Blaise D, Ghavamzadeh A, Passweg J, Ljungman P, Poiré X, Chevallier P, Reményi P, Rambaldi A, Anafasyev B, Fegueux N, Rovira M, Itälä-Remes M, Bornhäuser M, Mohty M, Nagler A.

Eur J Cancer. 2019 Jan;106:212-219. doi: 10.1016/j.ejca.2018.11.003. Epub 2018 Dec 6.

PMID:
30528805
8.

Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients.

Tichelli A, Beohou E, Labopin M, Socié G, Rovó A, Badoglio M, van Biezen A, Bader P, Duarte RF, Basak G, Salooja N; Transplant Complications Working Party of the EBMT.

JAMA Oncol. 2018 Nov 21. doi: 10.1001/jamaoncol.2018.4934. [Epub ahead of print]

PMID:
30476975
9.

Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT.

Schmid C, Labopin M, Schaap N, Veelken H, Schleuning M, Stadler M, Finke J, Hurst E, Baron F, Ringden O, Bug G, Blaise D, Tischer J, Bloor A, Esteve J, Giebel S, Savani B, Gorin NC, Ciceri F, Mohty M, Nagler A; EBMT Acute Leukaemia Working Party.

Br J Haematol. 2019 Mar;184(5):782-787. doi: 10.1111/bjh.15691. Epub 2018 Nov 22.

PMID:
30467839
10.

Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission.

Poiré X, Labopin M, Polge E, Blaise D, Chevallier P, Maertens J, Deconinck E, Forcade E, Rambaldi A, Baerlocher GM, Zuckerman T, Volin L, Schouten HC, Ifrah N, Mohty M, Esteve J, Nagler A.

Am J Hematol. 2019 Feb;94(2):231-239. doi: 10.1002/ajh.25355. Epub 2018 Dec 10.

PMID:
30456896
11.

Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis.

Canaani J, Beohou E, Labopin M, Ghavamzadeh A, Beelen D, Hamladji RM, Niederwieser D, Volin L, Markiewicz M, Arnold R, Mufti G, Ehninger G, Socié G, Kröger N, Mohty M, Nagler A.

J Intern Med. 2018 Oct 29. doi: 10.1111/joim.12854. [Epub ahead of print]

PMID:
30372796
12.

Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: A report of 1578 patients from the Acute Leukemia Working Party of EBMT.

Brissot E, Labopin M, Ehninger G, Stelljes M, Brecht A, Ganser A, Tischer J, Kröger N, Afanasyev B, Finke J, Elmaagacli A, Einsele H, Mohty M, Nagler A; Acute Leukemia Working Party of EBMT.

Haematologica. 2018 Oct 25. pii: haematol.2017.187450. doi: 10.3324/haematol.2017.187450. [Epub ahead of print]

13.

Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC.

Malard F, Labopin M, Cho C, Blaise D, Papadopoulos EB, Passweg J, O'Reilly R, Forcade E, Maloy M, Volin L, Castro-Malaspina H, Hicheri Y, Jakubowski AA, Orvain C, Giralt S, Mohty M, Nagler A, Perales MA.

J Hematol Oncol. 2018 Oct 20;11(1):127. doi: 10.1186/s13045-018-0668-3.

14.

Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study.

Bonifazi F, Dan E, Labopin M, Sessa M, Guadagnuolo V, Ferioli M, Rizzi S, De Carolis S, Sinigaglia B, Motta MR, Bontadini A, Giudice V, Martinelli G, Arpinati M, Cavo M, Bonafé M, Storci G.

Bone Marrow Transplant. 2018 Sep 19. doi: 10.1038/s41409-018-0335-x. [Epub ahead of print]

PMID:
30232415
15.

Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT.

Christopeit M, Labopin M, Gorin NC, Saraceni F, Passweg J, Forcade E, Maertens J, Van Lint MT, Bosi A, Niederwieser D, Ehninger G, Polge E, Mohty M, Nagler A.

Am J Hematol. 2018 Dec;93(12):1532-1542. doi: 10.1002/ajh.25285. Epub 2018 Oct 26.

PMID:
30218444
16.

Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine.

Giannotti F, Labopin M, Shouval R, Sanz J, Arcese W, Angelucci E, Sierra J, Santasusana JR, Santarone S, Benedetto B, Rambaldi A, Saccardi R, Blaise D, Carella MA, Rocha V, Baron F, Mohty M, Ruggeri A, Nagler A.

J Hematol Oncol. 2018 Aug 30;11(1):110. doi: 10.1186/s13045-018-0655-8.

17.

Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study.

Sengsayadeth S, Gatwood KS, Boumendil A, Labopin M, Finke J, Ganser A, Stelljes M, Ehninger G, Beelen D, Niederwieser D, Blaise D, Dreger P, Mufti G, Chevallier P, Mailhol A, Gilleece MH, Gorin N, Esteve J, Ciceri F, Baron F, Schmid C, Giebel S, Mohty M, Savani BN, Nagler A.

Blood Adv. 2018 Aug 28;2(16):2127-2135. doi: 10.1182/bloodadvances.2018019976.

18.

Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).

Canaani J, Labopin M, Huang XJ, Ciceri F, Van Lint MT, Bruno B, Santarone S, Diez-Martin JL, Blaise D, Chiusolo P, Wu D, Mohty M, Nagler A.

Br J Haematol. 2018 Nov;183(3):411-420. doi: 10.1111/bjh.15540. Epub 2018 Aug 16.

PMID:
30117144
19.

Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Lee CJ, Savani BN, Mohty M, Gorin NC, Labopin M, Ruggeri A, Schmid C, Baron F, Esteve J, Giebel S, Ciceri F, Nagler A.

Bone Marrow Transplant. 2018 Aug 13. doi: 10.1038/s41409-018-0286-2. [Epub ahead of print]

PMID:
30104717
20.

Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis.

Sheth V, Labopin M, Canaani J, Volin L, Brecht A, Ganser A, Mayer J, Labussière-Wallet H, Bittenbring J, Shouval R, Savani B, Mohty M, Nagler A.

Bone Marrow Transplant. 2018 Aug 7. doi: 10.1038/s41409-018-0288-0. [Epub ahead of print]

PMID:
30087463
21.

Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission.

Lorentino F, Labopin M, Bernardi M, Ciceri F, Socié G, Cornelissen JJ, Esteve J, Ruggeri A, Volin L, Yacoub-Agha I, Craddock C, Passweg J, Blaise D, Gedde-Dahl T, Poiani M, Fegueux N, Mohty M, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Am J Hematol. 2018 Oct;93(10):1236-1244. doi: 10.1002/ajh.25231. Epub 2018 Sep 3.

PMID:
30058714
22.

European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation.

Engel N, Rovo A, Badoglio M, Labopin M, Basak GW, Beguin Y, Guyotat D, Ljungman P, Nagler A, Schattenberg A, Schroeder T, Schroyens W, Tischer J, Socie G, Kolb HJ, Tichelli A, Salooja N, Duarte RF; Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation.

Leukemia. 2019 Feb;33(2):508-517. doi: 10.1038/s41375-018-0218-6. Epub 2018 Jul 26.

23.

Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.

Saraceni F, Beohou E, Labopin M, Arcese W, Bonifazi F, Stepensky P, Aljurf M, Bruno B, Pioltelli P, Passweg J, Sociè G, Santarone S, Yakoub-Agha I, Lanza F, Savani BN, Mohty M, Nagler A; Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).

Am J Hematol. 2018 Oct;93(10):1211-1219. doi: 10.1002/ajh.25225. Epub 2018 Aug 15.

PMID:
30033639
24.

Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Heinicke T, Labopin M, Schmid C, Polge E, Socié G, Blaise D, Mufti GJ, Huynh A, Brecht A, Ledoux MP, Cahn JY, Milpied N, Scheid C, Hicheri Y, Mohty M, Savani BN, Nagler A.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2224-2232. doi: 10.1016/j.bbmt.2018.07.007. Epub 2018 Aug 7.

PMID:
30009981
25.

Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse.

Kharfan-Dabaja MA, Labopin M, Polge E, Nishihori T, Bazarbachi A, Finke J, Stadler M, Ehninger G, Lioure B, Schaap N, Afanasyev B, Yeshurun M, Isaksson C, Maertens J, Chalandon Y, Schmid C, Nagler A, Mohty M.

JAMA Oncol. 2018 Sep 1;4(9):1245-1253. doi: 10.1001/jamaoncol.2018.2091.

PMID:
30003233
26.

Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.

Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Socié G, Ljungman P, Huynh A, Deconinck E, Wu D, Bourhis JH, Cahn JY, Polge E, Mohty M, Savani BN, Nagler A.

Am J Hematol. 2018 Sep;93(9):1142-1152. doi: 10.1002/ajh.25211. Epub 2018 Aug 15.

PMID:
29981272
27.

Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia.

Bond J, Labis E, Marceau-Renaut A, Duployez N, Labopin M, Hypolite G, Michel G, Ducassou S, Boutroux H, Nelken B, Bertrand Y, Baruchel A, Petit A, Asnafi V, Leverger G, Preudhomme C, Macintyre E, Lapillonne H.

Leukemia. 2018 Aug;32(8):1878-1882. doi: 10.1038/s41375-018-0187-9. Epub 2018 Jun 27. No abstract available.

PMID:
29950694
28.

The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation.

Fein JA, Shimoni A, Labopin M, Shem-Tov N, Yerushalmi R, Magen H, Furie N, Kopel E, Danylesko I, Nagler A, Shouval R.

Leukemia. 2018 Aug;32(8):1787-1794. doi: 10.1038/s41375-018-0185-y. Epub 2018 Jun 27.

PMID:
29950692
29.

Single-Dose Daily Fractionation Is Not Inferior to Twice-a-Day Fractionated Total-Body Irradiation Before Allogeneic Stem Cell Transplantation for Acute Leukemia: A Useful Practice Simplification Resulting From the SARASIN Study.

Belkacemi Y, Labopin M, Giebel S, Loganadane G, Miszczyk L, Michallet M, Socié G, Schaap NPM, Cornelissen JJ, Yakoub-Agha I, Polge E, Mohty M, Gorin NC, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):515-526. doi: 10.1016/j.ijrobp.2018.06.015. Epub 2018 Jun 19.

PMID:
29928948
30.

Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide.

Shimoni A, Labopin M, Lorentino F, Van Lint MT, Koc Y, Gülbas Z, Tischer J, Bruno B, Blaise D, Pioltelli P, Afanasyev B, Ciceri F, Mohty M, Nagler A.

Leukemia. 2019 Jan;33(1):230-239. doi: 10.1038/s41375-018-0170-5. Epub 2018 Jun 15.

PMID:
29907809
31.

Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?

Robinson TM, Fuchs EJ, Zhang MJ, St Martin A, Labopin M, Keesler DA, Blaise D, Bashey A, Bourhis JH, Ciceri F, Ciurea SO, Devine SM, Mohty M, McCurdy SR, Milpied N, McNiece IK, Rocha V, Romee R, Socie G, Yakoub-Agha I, Soiffer RJ, Eapen M, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplant and the Center for International Blood and Marrow Transplant Research.

Blood Adv. 2018 Jun 12;2(11):1180-1186. doi: 10.1182/bloodadvances.2018018291.

32.

Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes from the European Society for Blood and Marrow Transplantation.

Brierley CK, Castilla-Llorente C, Labopin M, Badoglio M, Rovira M, Ricart E, Dierickx D, Vermeire S, Hasselblatt P, Finke J, Onida F, Cassinotti A, Satsangi J, Kazmi M, López-Sanromán A, Schmidt C, Farge D, Travis SPL, Hawkey CJ, Snowden JA; European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP).

J Crohns Colitis. 2018 May 18. doi: 10.1093/ecco-jcc/jjy069. [Epub ahead of print]

33.

Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Salvatore D, Labopin M, Ruggeri A, Battipaglia G, Ghavamzadeh A, Ciceri F, Blaise D, Arcese W, Sociè G, Bourhis JH, Van Lint MT, Bruno B, Huynh A, Santarone S, Deconinck E, Mohty M, Nagler A.

Haematologica. 2018 Aug;103(8):1317-1328. doi: 10.3324/haematol.2018.189258. Epub 2018 May 10.

34.

Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT.

Giebel S, Labopin M, Potter M, Poiré X, Sengeloev H, Socié G, Huynh A, Afanasyev BV, Schanz U, Ringden O, Kalhs P, Beelen DW, Campos AM, Masszi T, Canaani J, Mohty M, Nagler A.

Eur J Cancer. 2018 Jun;96:73-81. doi: 10.1016/j.ejca.2018.03.018. Epub 2018 Apr 18.

PMID:
29679774
35.

Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study.

Sengsayadeth S, Labopin M, Boumendil A, Finke J, Ganser A, Stelljes M, Ehninger G, Beelen D, Niederwieser D, Blaise D, Dreger P, Mufti G, Chevallier P, Mailhol A, Gatwood KS, Gorin N, Esteve J, Ciceri F, Baron F, Schmid C, Giebel S, Mohty M, Savani BN, Nagler A.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1406-1414. doi: 10.1016/j.bbmt.2018.04.008. Epub 2018 Apr 17.

36.

AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation.

Halaburda K, Labopin M, Houhou M, Niederwieser D, Finke J, Volin L, Maertens J, Cornelissen JJ, Milpied N, Stuhler G, Kröger N, Esteve J, Mohty M, Nagler A.

Bone Marrow Transplant. 2018 Jun;53(6):683-691. doi: 10.1038/s41409-018-0165-x. Epub 2018 Apr 18.

PMID:
29670208
37.

Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia.

Battipaglia G, Ruggeri A, Labopin M, Volin L, Blaise D, Socié G, Tabrizi R, Cornelissen JJ, Ghavamzadeh A, Huynh A, Wu D, Yakoub-Agha I, Maertens J, Chevallier P, Mohty M, Nagler A.

Bone Marrow Transplant. 2018 Oct;53(10):1295-1303. doi: 10.1038/s41409-018-0169-6. Epub 2018 Apr 16.

PMID:
29662244
38.

Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT.

Santoro N, Labopin M, Giannotti F, Ehninger G, Niederwieser D, Brecht A, Stelljes M, Kröger N, Einsele H, Eder M, Hallek M, Glass B, Finke J, Ciceri F, Mohty M, Ruggeri A, Nagler A.

J Hematol Oncol. 2018 Apr 16;11(1):55. doi: 10.1186/s13045-018-0598-0.

40.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c.

PMID:
29634689
41.

Transfusion-related adverse events are decreased in pregnant women with sickle cell disease by a change in policy from systematic transfusion to prophylactic oxygen therapy at home: A retrospective survey by the international sickle cell disease observatory.

Ribeil JA, Labopin M, Stanislas A, Deloison B, Lemercier D, Habibi A, Albinni S, Charlier C, Lortholary O, Lefrere F, De Montalembert M, Blanche S, Galactéros F, Tréluyer JM, Gluckman E, Ville Y, Joseph L, Delville M, Benachi A, Cavazzana M.

Am J Hematol. 2018 Jun;93(6):794-802. doi: 10.1002/ajh.25097. Epub 2018 Apr 17.

42.

Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT.

Czerw T, Labopin M, Giebel S, Socié G, Volin L, Fegueux N, Masszi T, Blaise D, Chaganti S, Cornelissen JJ, Passweg J, Maertens J, Itälä-Remes M, Wu D, Mohty M, Nagler A.

Cancer. 2018 Jun 15;124(12):2523-2533. doi: 10.1002/cncr.31354. Epub 2018 Mar 30.

PMID:
29603136
43.

Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph-negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation.

Czyz A, Labopin M, Giebel S, Socié G, Apperley J, Volin L, Reményi P, Yakoub-Agha I, Orchard K, Michallet M, Stuhler G, Chaganti S, Murray M, Aljurf M, Bloor A, Passweg J, Finke J, Mohty M, Nagler A.

Am J Hematol. 2018 Jun;93(6):778-785. doi: 10.1002/ajh.25091. Epub 2018 Mar 30.

PMID:
29574915
44.

Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen.

Baron F, Labopin M, Ruggeri A, Cornelissen JJ, Meijer E, Sengeloev H, Niederwieser D, De Groot MR, Schouten HC, Milpied N, Blaise D, Savani BN, Gluckman E, Mohty M, Nagler A.

Clin Cancer Res. 2018 Jun 15;24(12):2794-2803. doi: 10.1158/1078-0432.CCR-17-3622. Epub 2018 Mar 19.

45.

Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT.

Ruggeri A, Labopin M, Bacigalupo A, Afanasyev B, Cornelissen JJ, Elmaagacli A, Itälä-Remes M, Blaise D, Meijer E, Koc Y, Milpied N, Schouten HC, Kroeger N, Mohty M, Nagler A.

J Hematol Oncol. 2018 Mar 15;11(1):40. doi: 10.1186/s13045-018-0586-4.

46.

Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study.

Li Z, Labopin M, Ciceri F, Blaise D, Tischer J, Ehninger G, Van Lint MT, Koc Y, Santarone S, Forcade E, Castagna L, Polge E, Mailhol A, Ruggeri A, Mohty M, Savani BN, Nagler A.

Am J Hematol. 2018 Jun;93(6):769-777. doi: 10.1002/ajh.25087. Epub 2018 Apr 11.

PMID:
29536560
47.

T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Canaani J, Labopin M, Huang XJ, Arcese W, Ciceri F, Blaise D, Irrera G, Corral LL, Bruno B, Santarone S, Van Lint MT, Vitek A, Esteve J, Mohty M, Nagler A.

Am J Hematol. 2018 Jun;93(6):736-744. doi: 10.1002/ajh.25082. Epub 2018 Mar 23.

PMID:
29498106
48.

Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.

Picod A, Bonnin A, Battipaglia G, Giannotti F, Ruggeri A, Brissot E, Malard F, Médiavilla C, Belhocine R, Vekhoff A, Gueye MS, Lapusan S, Adaeva R, Isnard F, Legrand O, Baylatry MT, Joly AC, Labopin M, Duléry R, Mohty M.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1471-1475. doi: 10.1016/j.bbmt.2018.02.015. Epub 2018 Mar 1.

PMID:
29477779
49.

Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Tozatto-Maio K, Giannotti F, Labopin M, Ruggeri A, Volt F, Paviglianiti A, Kenzey C, Hayashi H, Cornelissen J, Michallet M, Karakasis D, Deconinck E, Rohrlich PS, de la Tour RP, Blaise D, Petersen E, D'Aveni M, Sengeloev H, Lamy T, Russell NH, Forcade E, Craddock CF, Nagler A, Gluckman E, Rocha V.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1657-1663. doi: 10.1016/j.bbmt.2018.02.014. Epub 2018 Mar 1.

PMID:
29477777
50.

Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center.

Ciurea SO, Labopin M, Socie G, Volin L, Passweg J, Chevallier P, Beelen D, Milpied N, Blaise D, Cornelissen JJ, Fegueux N, Polge E, Kongtim P, Rondon G, Esteve J, Mohty M, Savani BN, Champlin RE, Nagler A.

Cancer. 2018 May 15;124(10):2134-2141. doi: 10.1002/cncr.31311. Epub 2018 Feb 22.

PMID:
29469961

Supplemental Content

Loading ...
Support Center